The FDA told influenza vaccine makers they should add a warning about an increased febrile seizure risk in babies and ...

The U.S. Food and Drug Administration said a comprehensive review “found no increased” risk related to suicide among users of ...

The U.S. health regulator asked drugmakers on Tuesday to remove warnings about a potential risk of suicidal thoughts from ...

On Jan. 6, the FDA classified the recall as Class I, the most high-risk recall category. Consuming the product could cause ...

Concerns about GLP-1 drugs indicated for weight loss were first raised after the FDA's Adverse Event Reporting System ...

The U.S. health regulator on Tuesday asked drugmakers to remove label warnings about a potential risk of suicidal thoughts ...

The FDA said it wants suicide warnings to be taken off some popular weight-loss medications following a comprehensive safety ...

The request comes after a two-year review into reported links between GLP-1RAs and psychiatric adverse events.

HHS has denied any nefarious intent behind the FDA’s removal of the page. In a statement to Ars Technica, a representative ...

A more detailed review of data by the FDA showed that GLP-1 drugs do not increase the risk of suicidal ideation or behavior.

But, under anti-vaccine Health Secretary Robert F. Kennedy Jr.—who has numerous ties to the wellness industry—that FDA ...

FDA moves to strike suicide risk warnings from Saxenda, Wegovy, and Zepbound labels after analysis finds no increased risk.